Familial aggregation of Waldenström macroglobulinemia (WM) and related B-cell disorders (BCD) suggests a role for genetic factors, but few data address environmental influences. We designed a questionnaire-based study to examine clinical and environmental factors in a cohort of WM families with varying patterns of case aggregation. We analyzed data on 103 WM patients and 272 unaffected relatives from 35 multiple-case WM and 46 mixed WM/BCD kindred and 28 non-familial (sporadic) WM patients, using logistic regression models with generalized estimating equations to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for association. In this study population, the WM disease process appeared to be similar among patients regardless of family history. Familial WM patients were more likely than unaffected relatives to report a history of autoimmune disease (OR 2.27; 95%CI=1.21-4.28) and infections (OR 2.13; 95%CI=1.25-3.64). Familial WM patients were also more likely to report exposure to farming (OR 2.70; 95%CI=1.34-5.42), pesticides (OR 2.83; 95%CI=1.56-5.11), wood dust (OR 2.86,, and organic solvents (multiple case WM OR 4.21;
Introduction
Waldenström macroglobulinemia (WM) is classified as a type of non-Hodgkin lymphoma (NHL) characterized primarily by lymphoplasmacytic infiltrate in the bone marrow accompanied by hypersecretion of monoclonal immunoglobulin M (IgM). 1, 2 Clinical features of WM are variable, with many patients having asymptomatic or indolent disease, while others present with symptoms attributable to direct tumor infiltration and/or monoclonal serum IgM protein. 3 The incidence of WM is unknown because of changes in diagnostic criteria over time;
however, WM is predicted to be rare. 4 IgM monoclonal gammopathy of undetermined significance (MGUS) may precede development of WM. 5 While the true incidence of IgM MGUS is also unknown, prevalence data suggest that it is more common than WM. 6 Although age, race, gender, and preexisting IgM monoclonal gammopathy of undetermined significance (MGUS) are recognized risk factors, 7, 8 the etiology of WM is largely unknown. Environmental and occupational exposures, such as exposure to leather, rubber, dyes, and paints have been implicated in case reports. [9] [10] [11] In a small hospital-based case-control study of environmental and occupational exposures, WM patients were found to be slightly better educated, but no significant differences were found for other socioeconomic characteristics, occupational exposures, alcohol or tobacco use, medication history, or history of previous medical conditions. 12 The study of familial disease clusters is a useful approach for defining the clinical phenotype of specific disorders, identifying new susceptibility genes, and facilitating the understanding of the pathogenesis of hereditary and non-hereditary cancers at both the individual and population levels. 13 Although familial clustering of WM has been previously documented and a role for genetic predisposition has been suggested, 14, 15 until recently there were very For personal use only. on October 3, 2017. by guest www.bloodjournal.org From limited data regarding the risks for relatives of WM patients. Early descriptions of familial aggregation of WM focused on families presenting multiple cases of WM exclusively. 14, [16] [17] [18] Emerging data at the population 19, 20 and clinical 21 levels have confirmed that a diagnosis of WM confers significantly elevated risk for relatives of WM patients to be diagnosed with WM or a related B-cell disorder. In addition, the spectrum of familial WM may include relatives with IgM monoclonal gammopathy and/or immunologic disorders. 18, 22, 23 To begin to address the gaps in our understanding of familial WM and its etiology, we designed a questionnaire-based study in a large cohort of WM families that have been recruited by the National Cancer Institute to examine demographic, clinical, environmental, and occupational differences among WM families with varying degrees of case aggregation.
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Patients and methods The National Cancer Institute WM Family Registry
The National Cancer Institute of the National Institutes of Health has maintained a registry of WM-prone families for over 30 years. 24 Families are eligible for inclusion in the registry if they have a member diagnosed with WM accompanied by at least 1 other bloodline relative diagnosed with WM or another disease of interest, such as other B-cell disorders (BCD -including chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, or multiple myeloma), MGUS, or autoimmune disease. Because young age at onset may be associated with increased genetic risk, families having a single patient diagnosed with WM prior to age 40 are also eligible.
In addition, a limited number of WM patients who do not fulfill any of these criteria have been recruited to serve as a non-familial comparison group. Patients with the disorders of interest, together with their first-and second-degree bloodline relatives, are eligible for inclusion. More distantly related relatives may be included if they connect two cases or are otherwise informative. Families are ascertained through self-, physician-, or genetic counselor-referral. A variety of organized Institutional Review Board-approved recruitment methods have been undertaken; for example, an information brochure that describes the registry and related studies has been available for distribution at national hematology and oncology meetings, a letter soliciting referrals was sent to practicing hematologists in the United States in 2003, and information about the study has been made available on the National Cancer Institute's clinical trials website. Increasingly, patients are self-referred after learning about the registry through an Internet search or through WM patient advocacy organizations. Following verification of eligibility, families are initially classified based on the pattern of case aggregation as described above prior to further data collection. Because most families are followed indefinitely, At the time of this analysis, there were 36 multiple-case WM families, 48 mixed WM/BCD families, and 28 sporadic WM patients in the registry. We analyzed available data on all eligible consenting subjects from these families. Mounting evidence suggests that WM coaggregates and may share risk factors with other B-cell disorders 20 and that IgM-MGUS is a precursor condition for WM. 5, [24] [25] [26] In our analysis, we included 28 relatives who had a history of a non-WM B-cell disorder or MGUS and who completed questionnaires (see below) with the unaffected group. However, a sensitivity analysis based on excluding these 28 individuals from the control group did not change the results (data not shown).
Data collection
The study was conducted under the approval of the National Cancer Institute (NCI) Clinical Center Institutional Review Board, and all participants gave written informed consent for data collection and analysis in accordance with the Declaration of Helsinki. All participants completed a standardized self-administered questionnaire that included questions regarding demographic information, selected personal medical history, occupational history, and history of certain environmental exposures. Medical conditions of interest included selected autoimmune and/or rheumatologic diseases, chronic inflammatory and/or infectious conditions including asthma, chronic cholecystitis, chronic hepatitis, chronic sinusitis, or chronic bronchitis, and a limited number of other infections including pneumonia requiring hospitalization, tuberculosis, hepatitis, pyelonephritis, or osteomyelitis. Autoimmune diseases were categorized as systemic, organ-specific, or suspected, as previously described. 27 Participants were queried regarding allergies, which were classified as drug-, dietary-, or environmentally-related. Individuals who reported a history of allergy were further asked to identify the specific allergen(s) associated with their allergic history. History of hyposensitization therapy was not obtained. Because there was limited a priori evidence implicating specific environmental exposures, [9] [10] [11] [12] non-occupational environmental exposures of interest were addressed broadly in an exploratory fashion and included tobacco and alcohol use, as well as prolonged exposure to livestock and/or domestic animals, paints, glues, solvents, leather/metal cleaning compounds, wood dust, asbestos, and hair dye. We used these broad groupings and did not query individuals regarding exposure to specific chemical compounds because we lacked power to analyze more discrete categories. We used a history of at least 6 consecutive months of exposure as the threshold for classifying an individual as exposed to any given class of agent.
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Statistical Analysis
Means and frequencies for continuous and categorical variables were determined. We used unconditional logistic regression with generalized estimating equations (GEE) 28 to account for correlations within the families in the variance computation. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) from multivariable models adjusted for gender, continuous age, and family type. We assessed heterogeneity of the ORs from each of the family types (mixed vs. multiple-case WM families) using the likelihood ratio test (LRT). If the effects were not significantly different, we combined the different family types to compute a combined OR.
We present 95% CIs and p-values based on the independent working correlation matrix. Other working correlations yielded similar results (SAS 9.1; PROC GENMOD).
Results
We identified 131 WM patients (57 multiple-case, 46 mixed WM/BCD, 28 non-familial) and 272 unaffected family members (167 from multiple-case and 105 from mixed WM/BCD families, respectively) for whom questionnaire data were available.
Demographic information for participants according to family type is presented in Table   1 . Because of the relatively late age of onset of WM, more family members were available from generations younger than the cases (n=129, 47.4%) than from the same (n=108, 39.7%) or older Overall, WM patients were predominantly male, although the excess was more apparent among familial than non-familial WM patients (57.3% male vs. 46.4% male, respectively; p=0.37). The median age at diagnosis of WM was 59.0 years (95%CI: 56.7 -61.3) for familial WM patients and 62.2 years (95%CI: 57.9 -66.5) for non-familial patients ( 13 ) families were more likely to report having ever experienced symptoms.
However, we did not observe significant differences between groups stratified by family type for any other disease-related variable aside from symptoms (data not shown). Reported symptoms were similar among familial and non-familial patients. The most commonly reported symptoms included fatigue and malaise, followed by neurological symptoms and dyspnea.
Following diagnosis of WM, mean time to treatment was similar for familial and nonfamilial patients, but there was substantial variability between individuals. Among those receiving any form of treatment, most patients (76 familial and 22 non-familial; 73.8% vs.
78.6%, respectively; p=0.90) reported having received chemotherapy. Thirty-five patients (28 familial and 7 non-familial, 29.2% vs. 25.0%, respectively; p=0.97) reported having received plasmapheresis or supportive treatment (i.e., blood component transfusion) in addition to chemotherapy. Table 3 shows the distribution of selected medical conditions for all participants. No family members reported a history of amyloidosis. A single family member from a multiplecase WM family reported a history of hypogammaglobulinemia. We found no significant differences between familial and non-familial WM patients for any of the conditions of interest.
We then stratified familial WM patients by family type and found no significant differences between familial WM patients based on the pattern of WM and other BCD aggregation. Since unaffected family members tended to be younger than familial WM cases, we examined the risk of familial WM stratified by age <60 and ≥ 60 years to further evaluate the potential effect of age.
Formal assessment using the likelihood ratio test (LRT) revealed no differences between groups, with certain exceptions. The risk of WM associated with tonsillectomy and/or adenoidectomy, For personal use only. on October 3, 2017. by guest www.bloodjournal.org From organic solvents, and therapeutic radiation was higher in patients <60 years compared to those ≥ 60 years (LRT p-value: 0.02, 0.01, and 0.02, respectively).
We then estimated ORs and 95% CIs for the association of exposure histories with WM using all family data. We found that familial WM patients were significantly more likely than unaffected individuals to report a history of autoimmune disorders (OR 2.27, 95%CI=1.21-4.28;
p=0.01), specified infections (OR 2.13, 95%CI=1.25-3.64; p=0.005) and allergies (OR 1.94, 95%CI=1.09-3.46; p=0.02). Among autoimmune diseases, risk was significantly increased for organ-specific autoimmune diseases (OR 3.07, 95%CI=1.29-7.28; p=0.01). We also observed a similar nonsignificant elevation in risk for systemic and/or suspected autoimmune diseases (OR 1.86, 95%CI=0.82-4.23; p=0.14), which we combined into a single category because of small numbers. While the association with allergies was not entirely consistent, we saw some evidence of increased risk of WM associated with allergies, which seemed strongest for drug allergies (OR 1.75, 95%CI=0.94-3.24; p=0.08). For most conditions, the observed elevations in risks were similar for all familial WM patients, irrespective of familial aggregation pattern. The risk associated with a history of organ-specific autoimmune disease appeared to be higher for patients from mixed WM/BCD families (OR 5.42, 95%CI 1.67-17.53) compared to patients from multiple-case families (OR 1.74, 95%CI 0.52-5.84). However, there was no evidence of multiplicative interaction between organ-specific autioimmune disease and family type
We also collected information for potential environmental and occupational exposures for affected WM patients and unaffected family members (Table 4 ). Comparing cases only, we found no significant differences between familial and non-familial WM patients or between familial WM patients stratified by family type (data not shown). When comparing WM patients patients were overall less likely than their relatives to report a history of therapeutic radiation exposure, the OR was not significant when stratified by family type, and numbers were small.
Discussion
While it is now well-established that family members of WM patients face an increased risk for developing WM and related B-cell malignancies, 20 the etiologic basis of enhanced susceptibility in these families remains undefined. We have conducted, to our knowledge, the first large systematic assessment of patterns of familial aggregation of WM and other BCD to explore disease-specific characteristics of familial WM and to identify potential associations with a broad range of host and environmental factors.
Several features of WM emerged in this study in relation to disease characteristics and familial patterns of WM aggregation. First, in this study population, the nature and course of the WM disease process appeared to be similar in many respects in patients with and without a family history of WM or other BCD. We were unable to identify significant differences in features of clinical presentation, diagnosis, time to treatment or requirement for supportive treatment between groups. Overall, WM patients were more likely to be male, which has been noted in other studies of WM specifically 20,21 and NHL overall. [29] [30] [31] This association with male sex suggests that environmental and genetic factors that are shared among male relatives should be investigated in the future. Patients with WM from multiple-case families tended to be more likely than non-familial WM patients to be asymptomatic. Although we validated the histopathological diagnosis of WM in most patients, this observation could be due to diagnosis earlier in the disease course because of heightened surveillance in individuals with a family history of WM. Disease course in this group of patients may be better assessed by evaluating survival following onset of symptomatic disease. We do not yet have sufficient events in this cohort to determine whether there are survival differences associated with family history of WM.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Of particular interest are our findings that WM, particularly among familial WM patients, was associated with a personal history of autoimmune disease and selected infections. In contrast to an early report, 12 39 Likewise, other conditions associated with immune deficiency and/or chronic antigenic stimulation, such as hereditary immunodeficiency syndromes 40 and autoimmune disorders, 27, 41 have been found to be associated with increased risk of NHL.
Increased risk for WM specifically has been associated with both systemic and organ-specific autoimmune diseases overall and particularly with Sjögren syndrome, immune thrombocytopenic purpura, and Crohn disease. 35 Alternative explanations for our results include surveillance bias, which is an inherent limitation of surveys of this type. In addition, immune deficiency and disordered immune response, including autoimmune phenomena, might be a consequence of WM (i.e., 'reverse causation'), as has been observed for autoimmune thrombocytopenia and non-Hodgkin lymphoma. 42 If this were the case, it might then be reasonable to expect cases to report other symptoms, especially nonspecific symptoms such as fatigue or malaise, as well. In this cohort, however, over 40% of familial WM patients reported no symptoms prior to diagnosis.
Koshiol et al. 35 examined latency patterns associated with various conditions and found that increased risk of WM persisted for more than 5 years following a diagnosis of autoimmune For personal use only. on October 3, 2017. by guest www.bloodjournal.org From disease, suggesting that not all autoimmune disease can be attributed to undiagnosed WM.
Nonetheless, it will be important in future studies to obtain information regarding disease chronology and to incorporate specific latency thresholds to minimize potential surveillance bias.
Our results agree with prior studies and suggest that host factors relating to immune regulation and response to chronic antigenic stimulation may influence development of WM in families.
Nonetheless, they need to be interpreted with caution, given the large number of exposures and analyses.
In this exploratory study, we found that familial WM patients were significantly more likely than their unaffected relatives to report a history of exposure to farming, pesticides, solvents, and wood dust, suggesting a possible role for environmental factors in the development of familial WM. Apart from conditions related to immune response, data for other risk factors for WM are sparse. The only study addressing environmental exposures, to our knowledge, was a case-control analysis based on 65 WM cases that found no significant association between WM and specific occupational exposures or employment in particular industries or occupations. 12 That study was limited by small numbers and geographical constraints. In contrast, a wide variety of potential environmental exposures have been evaluated in relation to overall NHL risk.
Although the epidemiologic data have been mixed, 43 some data suggest more consistent small increases in risk for farming and pesticide and herbicide exposure, but not for solvents, hair dye, and asbestos. 44 Thus, our findings are consistent with the literature for NHL overall. Again, caution is warranted, given the number of exposures evaluated. However, when we applied a formal Bonferroni correction for 103 tests, pesticide (p=0.0006) and wood dust (p=0.0009) exposure remained highly suggestive. In addition, the associations of farming and pesticide exposure with WM were not substantively changed by taking geographical location into account.
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Our study has several strengths, including a high level of validation of the underlying malignancy, consistent definition of WM, comprehensive demographic, medical and exposure data, and inclusion of non-familial patients and unaffected family members. Limitations include relatively small numbers, which are an inevitable constraint in studies of rare diseases, and lack of systematic population-based ascertainment that may limit the generalizability of our findings.
Thus, power to detect biological differences between familial and non-familial WM was limited.
Because the study was designed to be exploratory, we did not have in-depth data (e.g., date of diagnosis or treatment) on non-malignant conditions of interest. As we assessed a wide range of exposures, multiple comparisons may result in chance findings. Nonetheless, this study represents the largest and best-characterized cohort of familial WM patients reported to date.
In summary, we found that features of familial and non-familial WM appear to be similar in most respects, regardless of family history. Our observations provide additional evidence implicating chronic immune stimulation in the development of WM. Based on our results, we hypothesize that both genetic and environmental factors may modulate susceptibility to WM and that familial WM may contain distinct subsets based on the pattern of B-cell disorders aggregating within families. These hypotheses may be tested once a gene or genes predisposing to WM is identified. Meanwhile, additional studies are needed to confirm our findings and to expand our understanding of WM. 
